Disclosed are methods, materials and devices for approximation of blood volume in a fluid, such as in a biological fluid collected during a surgical procedure. The method and devices include the use of a RBC flocculant, such as polyDADMAC, and an approximate blood hematocrit for the type of animal, as well as a calculated RBC packing ratio corresponding to the collection device being used. Also provided is a Blood Indicator Panel (BIP), comprising a series of markings calculated from an observed red blood settlement volume, the average animal type hematocrit, and a calculated RBC packing ratio ? value for the collection device. Pediatric (about 200 ml or 250 ml size container), adult human (about 1,000 ml-1,500 ml) and veterinary (about 500 ml-2,500 ml) collection containers are also disclosed, that include a RBC flocculant, for use in approximating blood volume in a fluid.

Disclosed is a multiple bag system for fractionating blood, the system including a fluid collecting bag including at least one outlet port; at least first and second sampling bags, each including at least one inlet port and at least one outlet port; and a fluid transfer unit to transfer fluid from the collecting bag to the sampling bags. The fluid transfer unit includes an acoustic sorter. Also disclosed is a method for fractionating blood into blood products.

Treatment methods are described using blood collected from a donor after subjecting thereof to remote conditioning such as remote ischemic conditioning via several episodes of short-term limb occlusion. Blood containing remote conditioning substances or a biologically active preparation containing such substances may be stored and used at a future time to afford a health benefit to the treatment subject. Extraction of remote conditioning substances may be done extracorporeally using dialysis or other blood processing methods following by returning of blood to the donor. Extraction of remote conditioning substances may be done during the time periods of their maximum presence in donor blood.

A medicine-holding body is disposed in a flow path of a nozzle portion of an adapter for blood dispensing. The medicine-holding body is formed of a plurality of fibers which is made of polyester and is bundled by aligning a longitudinal direction thereof in a flowing direction which is a direction in which blood flows. The medicine-holding body holds an anticoagulant for suppressing coagulation of blood, as a medicine to be mixed into blood. The surface area of the medicine-holding body is greater than or equal to 10 mm.sup.2 and less than 600 mm.sup.2. In a case where the surface area of the medicine-holding body is greater than or equal to 10 mm.sup.2, the concentration of the anticoagulant becomes greater than or equal to a lower limit value of 10 U/mL even under most severe conditions such as a dispensing speed of 500 L/second. In a case where the surface area of the medicine-holding body is less than 600 mm.sup.2, it is possible to maintain the occurrence rate of hemolysis to be less than or equal to 10%.

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.

Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologous, and the concentration of growth factors (e.g., platelet derived growth factor) is elevated relative to other samples isolated from the same subject. The platelet-rich plasma can be used to promote tissue regeneration, including wound healing, joint repair, hair growth, and the like. The compositions can be combined with stem cells and used to treat disorders otherwise treated with stem cells. The growth factors present in the samples can direct the differentiation of the stem cells.

Provided is a chamber configuration for a reverse flow centrifuge, and a reverse flow centrifuge system configured for low fluid volume and small radius rotation. The compact reverse flow centrifuge system has a reusable subsystem and a single use replaceable subsystem. The replaceable subsystem comprises a separation chamber, fluid delivery manifold and rotational mounting connecting the separation chamber to the fluid manifold. The single use replaceable subsystem provides a closed environment for execution of reverse flow centrifugation processes. The separation chamber has a substantially conical fluid enclosure portion connected to a neck portion, and a dip tube extends centrally through the conical fluid enclosure to provide a fluid path to the tip of the conical fluid enclosure.

Methods and systems are provided automatically removing air from a collection container for a blood product. The system comprises a disposable flow circuit including a tubing in fluid communication with the collection container and a durable hardware component. A programmable controller operates the pump in a first/forward direction to flow the target product into the collection container; determines that substantially all the target product has been pumped into the collection container; and operates the pump in the first/forward direction to pump a chase volume of air into the collection container along with any target product remaining in the tubing. In one embodiment, after the chase volume of air is pumped into the collection container, the controller operates the pump in a second/reverse direction for removing air from the collection container, and stops operation of the pump when the amount of air removed from the collection container is substantially equal to the residual volume of air.

Treatment methods are described using blood collected from a donor after subjecting thereof to remote conditioning such as remote ischemic conditioning via several episodes of short-term limb occlusion. Blood containing remote conditioning substances or a biologically active preparation containing such substances may be stored and used at a future time to afford a health benefit to the treatment subject. Extraction of remote conditioning substances may be done extracorporeally using dialysis or other blood processing methods following by returning of blood to the donor. Extraction of remote conditioning substances may be done during the time periods of their maximum presence in donor blood.

A method of producing serum or plasma comprises the steps of drawing a blood sample from a subject; adding erythrocyte sedimentation-accelerating agent(s) and an anticoagulant to the blood sample; placing the mixture in a vessel with an inclined well and allowing the phase separation of the solution into an erythrocyte phase and a plasma or serum phase, producing an erythrocyte-depleted serum or plasma; and collecting the erythrocyte-depleted serum or plasma. A method of producing an ophthalmic solution (eye drops) meant for lubricating the eye of a subject comprises the steps of drawing a blood sample from a subject; adding erythrocyte sedimentation-accelerating agent(s) and an anticoagulant to the blood sample; placing the mixture in a vessel with an inclined well and allowing the phase separation of the solution into an erythrocyte phase and a plasma or serum phase, producing an erythrocyte-depleted serum or plasma; collecting the erythrocyte-depleted serum or plasma; treating the plasma with a platelet activating substance or agent; and applying the erythrocyte-depleted serum or plasma to the eye of the subject. A kit provides components, diagrams, compositions and instructions for performing the methods.